Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients

Therapeutic Drug Monitoring

Volumn 28, Issue 6, 2006, Pages 744-749

  Molden, Espen ^a   Lunde, Hilde ^a   Lunder, Niclas ^a   Refsum, Helge ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

Author keywords

Aripiprazole; Dehydroaripiprazole; LC MS MS; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

ARIPIPRAZOLE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEHYDROARIPIPRAZOLE; DRUG METABOLITE; FLUOXETINE; PAROXETINE;

ADOLESCENT; ADULT; BLOOD SAMPLING; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DRUG MONITORING; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PIPERAZINES; QUINOLONES;

EID: 33845713415     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000249944.42859.bf     Document Type: Conference Paper

References (22)

1. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004;10:317-336.
2. Aripiprazole/Abilify® prescription information. Available at: www.abilify.com. Accessed March 24, 2006.
3. Citrome L, Josiassen R, Bark N, et al. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol. 2005;45:89-93.
4. Dahl ML. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet. 2002;41:453-470.
5. Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci. 2003;28:99-112.
6. Baumann P, Hiemke C, Ulrich S, et al. Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. Ther Drug Monit. 2004;26:167-170.
7. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265.
8. Travis MJ, Burns T, Dursun S, et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract. 2005;59:485-495.
9. Hiemke C, Dragicevic A, Grunder G, et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit. 2004;26:156-160.
10. Kubo M, Mizooku Y, Hirao Y, et al. Development and validation of an LC-MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;822:294-299.
11. Kubo M, Koue T, Inaba A, et al. Influence of itraconazole coadministration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. Drug Metab Pharmacokinet. 2005;20:55-64.
12. Westlind-Johnsson A, Malmebo S, Johansson A, et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos. 2003;31:755-761.
13. Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol. 2002;62:162-172.
14. Weiss U, Marksteiner J, Kemmler G, et al. Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol. 2005;25:570-574.
15. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003;25:46-53.
16. Linnet K, Olesen OV. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication. Ther Drug Monit. 2002;24:512-517.
17. Carrillo JA, Herraiz AG, Ramos SI, et al. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol. 2003;23:119-127.
18. Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt). 2005;14:19-29.
19. Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology. 2002;27:248-259.
20. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64:1715-1736.
21. Kirschbaum KM, Muller MJ, Zernig G, et al. Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection. Clin Chem. 2005;51:1718-1721.
22. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004;44:179-187.